102 related articles for article (PubMed ID: 6435131)
1. The role of glucan in the prevention and modification of microparasitic diseases.
Di Luzio NR; Williams DL
Prog Clin Biol Res; 1984; 161():443-56. PubMed ID: 6435131
[No Abstract] [Full Text] [Related]
2. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan).
de Felippe Júnior J; da Rocha e Silva Júnior M; Maciel FM; Soares Ade M; Mendes NF
Surg Gynecol Obstet; 1993 Oct; 177(4):383-8. PubMed ID: 8211583
[TBL] [Abstract][Full Text] [Related]
3. Use of glucan and other immunopharmacological agents in the prevention and treatment of acute radiation injuries.
Patchen ML; Chirigos MA; Brook I
Fundam Appl Toxicol; 1988 Nov; 11(4):573-4. PubMed ID: 3229582
[No Abstract] [Full Text] [Related]
4. [Beta-1,3-glucan and other immunomodulators in experimental leprosy infection in mice].
Delville J; Jacques PJ
Acta Leprol; 1979; (76-77):273-81. PubMed ID: 121844
[No Abstract] [Full Text] [Related]
5. [beta-1, 3 glucan as an immunopotentiator against experimental tuberculous infection in mice (author's transl)].
Kanai K; Kondo E
Kekkaku; 1980 Aug; 55(8):371-4. PubMed ID: 7420811
[No Abstract] [Full Text] [Related]
6. Concepts of immunostimulation to increase antiparasitic drug action.
Masihi KN
Parasitol Res; 2003 Jun; 90 Suppl 2():S97-S104. PubMed ID: 12937971
[No Abstract] [Full Text] [Related]
7. Anthrax-protective effects of yeast beta 1,3 glucans.
Kournikakis B; Mandeville R; Brousseau P; Ostroff G
MedGenMed; 2003 Mar; 5(1):1. PubMed ID: 12827062
[TBL] [Abstract][Full Text] [Related]
8. [Immunostimulatory sequence and DNA vaccine].
Zhao S; Zhu YC
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2004 Apr; 22(2):122-5. PubMed ID: 15281461
[No Abstract] [Full Text] [Related]
9. [The approaches of the Russian school of parasitologists and immunologists to the therapy of parasitic diseases].
Ozeretskovskaia NN
Med Parazitol (Mosk); 1998; (2):12-5. PubMed ID: 9691613
[No Abstract] [Full Text] [Related]
10. [Chemotherapy of parasitic diseases and immunodepression].
Ozeretskovskaia NN
Med Parazitol (Mosk); 1980; 49(5):3-12. PubMed ID: 6999322
[No Abstract] [Full Text] [Related]
11. Immunomodulation of protozoan diseases. Potential of glucan as an adjuvant.
Cook JA; Runey GL; Holbrook TW
Surv Immunol Res; 1983; 2(3):243-5. PubMed ID: 6675146
[No Abstract] [Full Text] [Related]
12. Application of beta-1,3-glucan to prevent shipping fever in imported heifers.
Pedroso M
Arch Med Res; 1994; 25(2):181. PubMed ID: 7919809
[TBL] [Abstract][Full Text] [Related]
13. Yeast glucan and immunotherapy of infectious diseases.
Song M; di Luzio NR
Front Biol; 1979; 48():533-47. PubMed ID: 387468
[No Abstract] [Full Text] [Related]
14. [Experimental studies on the use of an immunoadjuvant (beta-1, 3 glucan) to prevent relapse after termination of chemotherapy in mouse model (author's transl)].
Kondo E; Kanai K
Kekkaku; 1980 Sep; 55(9):411-4. PubMed ID: 7431726
[No Abstract] [Full Text] [Related]
15. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
[TBL] [Abstract][Full Text] [Related]
16. [Vaccines against parasites?].
Lang W
MMW Munch Med Wochenschr; 1981 Jan; 123(1):21-2. PubMed ID: 6780883
[No Abstract] [Full Text] [Related]
17. Complement function in mAb-mediated cancer immunotherapy.
Gelderman KA; Tomlinson S; Ross GD; Gorter A
Trends Immunol; 2004 Mar; 25(3):158-64. PubMed ID: 15036044
[No Abstract] [Full Text] [Related]
18. Carbohydrate polymers: new immune system modifying agents for infectious diseases.
Oncology (Williston Park); 1991 Mar; 5(3):117-8. PubMed ID: 1829938
[No Abstract] [Full Text] [Related]
19. Controversies on the prevention of insulin-dependent diabetes mellitus by immunomodulation: lessons from NOD mice treated with beta-1,6;1,3-D-glucan and rhIGF-I.
Kida K; Kaino Y; Ito T; Hirai H
J Pediatr Endocrinol Metab; 1998 Apr; 11 Suppl 2():327-33. PubMed ID: 9642663
[No Abstract] [Full Text] [Related]
20. [Further study of immunopotentiation in experimental antiblastic therapy by inactivated yeasts and glucan].
Delfina Pesce C; Boccanera M; Marconi P; Bistoni F; Cenci E; Tissi L; Cassone A
Ann Ist Super Sanita; 1982; 18(3):509-12. PubMed ID: 7187836
[No Abstract] [Full Text] [Related]
[Next] [New Search]
